Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls

World Journal of Gastroenterology

Volumn 10, Issue 11, 2004, Pages 1643-1646

  Zhang, Bo ^a   Chen, Jian Ying ^a   Chen, Dao Da ^a   Wang, Guo Bin ^a   Shen, Ping ^b  

^a UNION HOSPITAL   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EDETIC ACID; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BODY FLUID; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC KIT; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; STANDARD; STATISTICAL SIGNIFICANCE; STOMACH CANCER; COLORECTAL TUMOR; ENZYMOLOGY; METABOLISM; PATHOLOGY; STOMACH TUMOR;

COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASM STAGING; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 2942709910     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i11.1643     Document Type: Article

References (32)

1. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 2002; 87(Suppl 1): S23-29
2. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003; 23: 1149-1154
3. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 2001; 356(Pt 1): 247-256
4. Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp, S, Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 2000; 20: 5151-5154
5. Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res 2003; 23(2A): 1127-1130
6. Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res 1999; 19(4A): 2753-2757
7. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1999; 96: 1291-1296
8. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000; 24: 531-535
9. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol 2001; 22: 282-285
10. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20: 4965-4968
11. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 2000; 20: 4961-4964
12. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Anticancer Res 2003; 23(2A): 855-857
13. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23(2A): 851-853
14. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 1999; 19: 2599-2601
15. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19(4A): 2583-2590
16. Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res 2000; 20: 5095-5098
17. Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K, Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 26
18. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urologe A 2000; 39: 554-556
19. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000; 20: 5053-5058
20. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22(1A): 311-318
21. Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Anticancer Res 2003; 23(2A): 899-906
22. Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med 2003; 2: 185-191
23. Pottek T, Muller M, Blum T, Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20: 5029-5033
24. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-5082
25. Hoopmann M, Warm M, Mallmann P, Thomas A, Gohring UJ, Schondorf T. Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 2002; 187: 223-228
26. Schneider J, Neu K, Velcovsky HG, Morr H, Eigenbrodt E. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 2003; 193: 91-98
27. Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H. Tumor M2-PK levels in haematological malignancies. Anticancer Res 2003; 23(2A): 1135-1138
28. Oremek GM, Muller R, Sapoutzis N, Wigand R. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases. Anticancer Res 2003; 23: 1131-1134
29. Aisaki K, Kanno H, Oyaizu N, Hara Y, Miwa S, Ikawa Y. Apoptotic changes precede mitochondrial dysfunction in red cell-type pyruvate kinase mutant mouse erythroleukemia cell lines. Jpn J Cancer Res 1999; 90: 171-179
30. Steinberg P, Klingelhoffer A, Schafer A, Wust G, Weisse G, Oesch F, Eigenbrodt E. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch 1999; 434: 213-220
31. Oremek GM, Rutner F, Sapoutzis N, Sauer-Eppel H. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy. Anticancer Res 2003; 23(2A): 1155-1158
32. Pezzilli R, Migliori M, Morselli-Labate AM, Campana D, Ventrucci M, Tomassetti P, Corinaldesi R. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Anticancer Res 2003; 23: 2969-2972